Literature DB >> 29700096

Surveillance for hepatocellular cancer.

Anna Roskilly1, Ian A Rowe2.   

Abstract

Hepatocellular carcinoma (HCC) is a common complication of cirrhosis. The incidence of HCC is rising and HCC-related mortality is rising in parallel such that there were more than 1,700 deaths in the UK in 2015. Since cirrhosis is a known risk factor for the development of HCC and early diagnosis is associated with improved outcomes, surveillance for the development of HCC using regular ultrasound scans is recommended by many expert bodies including the National Institute for Health and Care Excellence (NICE). This surveillance is not supported by high-quality evidence and there is an increasing appreciation of the associated harms. In this review the likely benefits of surveillance are discussed together with recommendations to increase the effectiveness of surveillance overall. © Royal College of Physicians 2018. All rights reserved.

Entities:  

Keywords:  Hepatocellular cancer; cirrhosis; liver failure; non-alcoholic fatty liver disease; surveillance

Mesh:

Year:  2018        PMID: 29700096      PMCID: PMC6334024          DOI: 10.7861/clinmedicine.18-2-s66

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


  30 in total

1.  Surveillance for hepatocellular carcinoma is associated with increased survival: Results from a large cohort in the Netherlands.

Authors:  Suzanne van Meer; Robert A de Man; Minneke J Coenraad; Dave Sprengers; Karin M J van Nieuwkerk; Heinz-Josef Klümpen; Peter L M Jansen; Jan N M IJzermans; Martijn G H van Oijen; Peter D Siersema; Karel J van Erpecum
Journal:  J Hepatol       Date:  2015-06-20       Impact factor: 25.083

Review 2.  Screening for hepatocellular carcinoma in chronic liver disease: a systematic review.

Authors:  Devan Kansagara; Joel Papak; Amirala S Pasha; Maya O'Neil; Michele Freeman; Rose Relevo; Ana Quiñones; Makalapua Motu'apuaka; Janice H Jou
Journal:  Ann Intern Med       Date:  2014-08-19       Impact factor: 25.391

3.  Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort).

Authors:  Jean-Claude Trinchet; Valérie Bourcier; Cendrine Chaffaut; Mohand Ait Ahmed; Setty Allam; Patrick Marcellin; Dominique Guyader; Stanislas Pol; Dominique Larrey; Victor De Lédinghen; Denis Ouzan; Fabien Zoulim; Dominique Roulot; Albert Tran; Jean-Pierre Bronowicki; Jean-Pierre Zarski; Odile Goria; Paul Calès; Jean-Marie Péron; Laurent Alric; Marc Bourlière; Philippe Mathurin; Jean-Frédéric Blanc; Armand Abergel; Lawrence Serfaty; Ariane Mallat; Jean-Didier Grangé; Catherine Buffet; Yannick Bacq; Claire Wartelle; Thông Dao; Yves Benhamou; Christophe Pilette; Christine Silvain; Christos Christidis; Dominique Capron; Gérard Thiefin; Sophie Hillaire; Vincent Di Martino; Pierre Nahon; Sylvie Chevret
Journal:  Hepatology       Date:  2015-03-20       Impact factor: 17.425

4.  Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail?

Authors:  Amit G Singal; Mahendra Nehra; Beverley Adams-Huet; Adam C Yopp; Jasmin A Tiro; Jorge A Marrero; Anna S Lok; William M Lee
Journal:  Am J Gastroenterol       Date:  2013-01-22       Impact factor: 10.864

Review 5.  Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

Authors:  Zobair M Younossi; Aaron B Koenig; Dinan Abdelatif; Yousef Fazel; Linda Henry; Mark Wymer
Journal:  Hepatology       Date:  2016-02-22       Impact factor: 17.425

Review 6.  Hepatocellular carcinoma: clinical frontiers and perspectives.

Authors:  Jordi Bruix; Gregory J Gores; Vincenzo Mazzaferro
Journal:  Gut       Date:  2014-02-14       Impact factor: 23.059

7.  Randomized controlled trial of screening for hepatocellular carcinoma.

Authors:  Bo-Heng Zhang; Bing-Hui Yang; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-07       Impact factor: 4.553

8.  Diagnosis of liver cirrhosis in England, a cohort study, 1998-2009: a comparison with cancer.

Authors:  Sonia Ratib; Joe West; Colin J Crooks; Kate M Fleming
Journal:  Am J Gastroenterol       Date:  2014-01-14       Impact factor: 10.864

9.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

10.  Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis.

Authors:  Amit G Singal; Anjana Pillai; Jasmin Tiro
Journal:  PLoS Med       Date:  2014-04-01       Impact factor: 11.069

View more
  3 in total

1.  High mobility group box 3 as an emerging biomarker in diagnosis and prognosis of hepatocellular carcinoma.

Authors:  Wenjie Zheng; Junling Yang; Zhizhen Dong; Li Wang; Miao Fang; Wei Wu; Dengfu Yao; Min Yao
Journal:  Cancer Manag Res       Date:  2018-11-20       Impact factor: 3.989

2.  Cyclin-Dependent Kinase 4 is expected to be a therapeutic target for hepatocellular carcinoma metastasis using integrated bioinformatic analysis.

Authors:  Jia-Ning Zhang; Feng Wei; Lin-Han Lei; Yang Yang; Yuan Yang; Wei-Ping Zhou
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

3.  Apigetrin Promotes TNFα-Induced Apoptosis, Necroptosis, G2/M Phase Cell Cycle Arrest, and ROS Generation through Inhibition of NF-κB Pathway in Hep3B Liver Cancer Cells.

Authors:  Pritam Bhagwan Bhosale; Abuyaseer Abusaliya; Hun Hwan Kim; Sang Eun Ha; Min Yeong Park; Se Hyo Jeong; Preethi Vetrivel; Jeong Doo Heo; Jin-A Kim; Chung Kil Won; Hyun-Wook Kim; Gon Sup Kim
Journal:  Cells       Date:  2022-09-01       Impact factor: 7.666

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.